RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS

RedHill Biopharma Ltd.

21 Ha'arba'a Street
Tel Aviv 64739
Israel
972 3 541 3131
http://www.redhillbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees74

Key Executives

NameTitlePayExercisedYear Born
Mr. Dror Ben-AsherCo-Founder, Chairman & CEO333.32kN/A1966
Mr. Micha Ben-ChorinChief Financial Officer223.8kN/A1969
Mr. Gilead RadayChief Operating Officer302.2kN/A1975
Dr. Reza FathiSr. VP of R&D267.01kN/A1955
Mr. Guy GoldbergChief Bus. Officer221.4kN/A1976
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILS.

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Corporate Governance

RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.